Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co-Expression Patterns: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial
The added GIP and glucagon activity is intended to enhance weight loss and metabolic effects in research settings
Originally derived from a protective protein found in the stomach, BPC-157 has gained popularity for its regenerative properties, making it a top choice for those recovering from injuries or surgery
In stock No certificates are available for this product yet
Mitternacht, S
phase 3 trials ongoing as of 2025 Best phase 2 weight loss (retatrutide) / 24.2% at 48 weeks, 12 mg dose Best phase 3 weight loss (tirzepatide) / 22.5% at 72 weeks, 15 mg dose Combination evidence / zero published controlled trials Primary combination risk / additive nausea, vomiting, potential pancreatitis Switching rationale / inadequate response or tolerability on tirzepatide Guideline position on combining / no major guideline endorses dual-incretin stacking What Are Mounjaro and Retatrutide, and How Do They Differ
